Status:
COMPLETED
Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it. However, people with atrial fibrillation are also at increas...
Eligibility Criteria
Inclusion
- Diagnosis of ACS defined by a hospital discharge (ICD-10 code of I21 for myocardial infarction or I20.0 for unstable angina pectoris (with or without sub-codes) during the study period and a diagnosis of AF (ICD-10 code I48 with or without sub-codes) in the Patient Register before or on the same day as the patient was discharged for ACS.
Exclusion
- \- No exclusions will be made as the registries capture the entire life-time of entire population of Sweden.
Key Trial Info
Start Date :
November 16 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 23 2018
Estimated Enrollment :
14226 Patients enrolled
Trial Details
Trial ID
NCT03311139
Start Date
November 16 2017
End Date
March 23 2018
Last Update
January 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many locations
Multiple Locations, Sweden